← back to search

Daniel S. Kapp

Palo Alto University · US
Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Medicine, Incidence (geometry), Ovarian cancer, Cervical cancer, Internal medicine, and Oncology.
h-index
citations
699
works
27
NIH funding
primary concept
email

Recent publications

Management Based on Pretreatment PSMA PET of Patients with Localized High-Risk Prostate Cancer Part 2: Prediction of Recurrence—A Systematic Review and Meta-Analysis
Cancers 2025cited by 3position: middledoi
Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes
Gynecologic Oncology 2024cited by 8position: middledoi
Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
Biomedicines 2023cited by 4position: middledoi
Differences in the mutational landscape directing targeted therapies for Black and White patients with endometrial cancer (2113)
Gynecologic Oncology 2023cited by 1position: middledoi
Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017
JAMA Network Open 2022cited by 157position: middledoi
The increasing incidence of stage IV cervical cancer in the USA: what factors are related?
International Journal of Gynecological Cancer 2022cited by 60position: middledoi
The effect of COVID‐19 on telehealth: Next steps in a post‐pandemic life
International Journal of Gynecology & Obstetrics 2022cited by 2position: middledoi
EP169/#289 Trends in uterine cancer mortality in United States: a 50-year population-based analysis
International Journal of Gynecological Cancer 2022cited by 1position: middledoi
Geographic trends in rare uterine sarcomas: could environment affect incidence? (403)
Gynecologic Oncology 2022cited by 0position: middledoi
The impact of age, race, and HPV status on the increasing incidence of cervical adenocarcinoma in U.S. women
Gynecologic Oncology 2021cited by 1position: middledoi
Racial disparities in prevalence of homologous recombination deficiency in ovarian, uterine, and cervical cancer tumors
Gynecologic Oncology 2021cited by 1position: middledoi
The increasing incidence of uterine serous cancers in the elderly and Black women: what molecular markers can guide novel treatment approaches for these patients?
Gynecologic Oncology 2021cited by 0position: middledoi
The influence of age, race, and histology on the expression of preoperative CA-125 in stage I epithelial ovarian cancer patients
Gynecologic Oncology 2021cited by 0position: middledoi
The increasing incidence of granulosa cell tumors in the United States: what factors are responsible?
Gynecologic Oncology 2021cited by 0position: middledoi
A clinical calculator to personalize chemotherapy in early-stage clear cell ovarian cancer
Gynecologic Oncology 2021cited by 0position: middledoi
The increasing incidence of uterine cancers in younger women
Gynecologic Oncology 2021cited by 0position: middledoi
The overall decrease in incidence of ovarian cancer in the United States: is this reflected in our racial ethnic groups?
Gynecologic Oncology 2021cited by 0position: middledoi
CA-125 and other prognostic factors associated with survival in stage I epithelial ovarian cancer: a study of 15,882 patients
Gynecologic Oncology 2021cited by 0position: middledoi
Cervical cancer trends in Hispanic subgroups: who is most at risk?
Gynecologic Oncology 2021cited by 0position: middledoi
The increasing incidence of uterine serous cancers in the elderly and Black women: what molecular markers can guide novel treatment approaches for these patients?
Gynecologic Oncology 2021cited by 0position: middledoi
Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes
Clinical & Experimental Metastasis 2019cited by 103position: middledoi
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients
Gynecologic Oncology 2019cited by 27position: middledoi
Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US
Gynecologic Oncology 2018cited by 55position: middledoi
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients
Gynecologic Oncology 2015cited by 17position: middledoi
MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer
Gynecologic Oncology 2014cited by 94position: middledoi
Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States
Gynecologic Oncology 2014cited by 74position: middledoi
Primary squamous cell carcinoma of the vagina: Prognostic factors, treatment patterns, and outcomes
Gynecologic Oncology 2013cited by 91position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John K. Chan · Sutter Health19 papers (2014–2024)Cheng-I Liao · Dartmouth College15 papers (2018–2024)Kathleen M. Darcy · Palo Alto University10 papers (2021–2024)Chunqiao Tian · Palo Alto University10 papers (2021–2024)Amandeep Mann · Drexel University9 papers (2018–2021)Michael Richardson · University of California, Los Angeles8 papers (2021–2024)David Mysona · University of South Carolina6 papers (2021–2023)Kevin Tran · University of California, Berkeley3 papers (2021–2021) · 3 papers (2021–2021)Katherine C. Fuh · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2014–2019)G. Larry Maxwell · Roswell Park Comprehensive Cancer Center3 papers (2021–2024) · 3 papers (2021–2021)Austin B. Gardner · University of Alabama at Birmingham3 papers (2019–2021)Michelle Ann Caesar · California Pacific Medical Center2 papers (2022–2022)Lee-may Chen · Gynecologic Oncology Group2 papers (2014–2018)Ritu Salani · University of Colorado Cancer Center2 papers (2022–2023) · 2 papers (2023–2025)Kevin Blansit · University of California San Diego2 papers (2014–2015)Susan M. Lang · Palo Alto University2 papers (2022–2023) · 2 papers (2023–2025)